TALLAHASSEE, FL — (Marketwire) — 07/11/12 — Global Green, Inc. (OTCBB: GOGC) today announced they have been invited to present at the 2012 World Animal Health Congress, a senior-level B2B conference for animal drug companies.
The Congress, to be held November 27 and 28 in Kansas City, showcases innovation in animal health, featuring senior-level speakers from the pharma, biotech, diagnostics and government sectors.
“We are pleased to present at the 2012 World Animal Health Congress. This recognition of our unique vaccine, Salmogenics, is appreciated,” commented Dr. Mehran Ghazvini, Chairman and CEO.
Salmogenics helps to fight multiple strains of Salmonella bacteria in poultry. It is unique in that it is injected directly into the egg, before the chick is formed, improving the immune system, health and welfare of the chicken, and providing a healthier source of protein for humans in a cost effective manner.
The World Animal Health Congress, sponsored by Terrapinn, is a senior-level B2B conference for animal drug companies seeking the best business strategies to maximize returns. It is a place where innovation is showcased, learning takes place and new business contacts are made. By uniting senior-level animal health executives from big pharma together with CEOs and CSOs from leading small to mid-size pharma and biotechs, World Animal Health Congress USA provides an unrivalled platform to expose the most pressing business challenges of the industry. Discussing everything from regulatory compliance to delivering vet drugs to the market, it is the perfect opportunity to identify and approach new business prospects. For more information, visit .
Terrapinn is a business media company. Their products are trade exhibitions, conferences, training solutions, electronic and print publications. Terrapinn owns a portfolio of B2B brands. Established in Sydney, Australia in 1987, Terrapinn operates throughout the world from a network of offices in Sydney, Singapore, Johannesburg, New York, Dubai and London. The organization consists of approximately 400 staff and is led by an experienced management team headquartered in London.
Global Green, Inc. is a green pharmaceutical company committed to identifying technology platforms and commercializing products that contain natural organisms that are not genetically modified, utilizing pharmaceutical standards. Salmogenics, the Company–s flagship product, was developed by Nutritional Health Institute Laboratories, LLC, a research affiliate and majority shareholder. The vaccine is currently in the final stage of the USDA approval process. For more information, visit .
This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that such forward-looking statements involve risks and uncertainties, which include among others, the inherent uncertainties associated with smaller reporting companies, including without limitation, other risks detailed from time to time in the Company–s periodic reports filed with the Securities and Exchange Commission.
Contact
Pam Lagano
727.480.3082